Genentech anti-PD-L1 immunotherapy could be 1st bladder cancer drug in 20 years
Based on Genentech Inc.'s Phase I data presented last week at the American Society of Clinical Oncology meeting, the Roche unit could see swift uptake of its anti-PD-L1 antibody in the underserved indication of metastatic bladder cancer.
It has been more than 20 years since any new drugs were approved for metastatic bladder cancer, for which first-line standard of care is platinum-based chemotherapy.
About half of patients receiving SOC progress and are given additional chemotherapy regimens that in turn delay progression by only two to four months, according to Sumanta Pal, assistant professor in the department of medical oncology at City of Hope Comprehensive Cancer Center.
The median overall survival for patients who relapse on platinum-based chemotherapy is seven months.
"We don't have anything with durable responses," Pal told BioCentury.
Genentech presented data from a Phase I trial of MPDL3280A to